We have developed a serology test platform for identifying individuals with prior exposure to specific viral infections and provide data to help reduce public health risks.
Electrically regulated cell-based intervention for viral infections
This work reports on an engineered cell that—when electrically stimulated—synthesizes a desired protein, that is, ES-Biofactory.
Cell-Based Platform for Antigen Testing and Its Application for SARS-CoV-2 Infection
We have engineered a cell that can be used for diagnosing active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Antiviral T-cell Biofactory platform for SARS-CoV-2
We engineered a T cell to synthesize interferons (IFNs) as antiviral proteins upon recognizing the virus envelop protein of SARS-CoV-2, i.e., anti-SARS T-cell Biofactory.
NK-Cell Biofactory as an Off-the-Shelf Cell-based Vector for Targeted In Situ Synthesis of Engineered Proteins
NK-cell Biofactory is an off-the-shelf allogeneic platform for cell-based synthesis of desired protein following recognition of a target cell while conserving the cytolytic activity.
Lentivirus Manufacturing Process for Primary T‐Cell Biofactory Production
A process for maximizing the titer of lentivirus particles, deemed to be a necessity for transducing primary cells, is developed.
Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function
A set of genetically engineered isogenic cell lines is developed to express either folate receptor alpha or mesothelin, and a control cell line negative for both antigens.
Modular Antigen-Specific T-cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins
An artificial cell-signaling pathway is developed that capitalizes on the T-cell’s innate extravasation ability and transforms it into a vector for synthesizing calibrated amounts of engineered proteins in vivo.